VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer Clinical Trial

— VIC-1911  

Official title:

Phase I Clinical Study of VIC-1911 Combined With Osimertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGRF- Mutation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05489731
• Other study ID #: JSI-1911-102
• Status: Recruiting
• Phase: Phase 1
• Start date: September 21, 2022
• Est. completion date: April 24, 2024

Study information

• Verified date: June 2023
• Source: Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
• Contact: li zhang, professor
• Phone: 13902282893
• Email: zhangli6[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a nonrandomized, open phase I dose escalation and extension clinical study designed to evaluate Aurora A inhibitor VIC-1911 tablets in combination with oxitinib in Chinese patients with advanced non-small cell lung cancer The safety, tolerability, pharmacokinetic characteristics and preliminary antitumor efficacy were analyzed.

The entire study included the screening period (28 days prior to initialadministration of the investigational drug) and the treatment period (Cycle) EoT is defined as disease progression or intolerable toxicity or premature withdrawal Out]) and the safety follow-up period (28 days after EoT). During dose increments and expansions, subjects followed Safety assessment, PK blood collection, imaging examination and efficacy assessment were performed during the visit plan. Observation subject The safety, tolerability, and occurrence of DLT until disease progression, occurrence of intolerable toxicity, Death, withdrawal of informed consent, loss of follow-up or termination of the study by the sponsor shall prevail.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: April 24, 2024
• Est. primary completion date: February 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Voluntarily participate in clinical research, sign written informed consent, and be able to abide by clinical visits and research Relevant procedures;

2. Male or female patients aged 18-75 (including boundary value) when signing the informed consent form;

3. NSCLC with advanced EGFR mutation positive [exon 19 deletion (19del) and exon 21 L858R (21l858r) point mutation] confirmed by cytology or histology A. only applicable to the dose increasing stage: after receiving the first / second generation EGFR-TKI treatment failure T790M mutation negative or third-generation EGFR-TKI treatment failed, and then received platinum containing dual drug chemotherapy Terminal NSCLC patients after failure; B. only applicable to the expansion phase: (1) queue 1: after the treatment failure of the first / second generation EGFR-TKI NSCLC patients with T790M mutation positive; (2) Cohort 2: NSCLC patients who failed to receive three generations of EGFR-tki treatment;

4. According to RECIST 1.1 standard, patients must have a passing shadow Measurable lesions assessed by imaging examination;

5. The EC0G score is 0 or 1;

6. Estimated survival time = 3 months;

7. Bone marrow reserve and organ function level within 7 days before administration must meet the following requirements:

1. Bone marrow reserve: hemoglobin (HB) = 9.0 g/dl, absolute neutrophil count (ANC)= 1.5 × 109/l, platelet (PLT) = 100 × 109/l, opened during the study treatment period Blood transfusion (whole blood, platelets or red blood cells) is prohibited 1 month before the start;

2. Coagulation function: international normalized ratio (INR) = 1.5 × Upper normal value (ULN), active Partial prothrombin time (APTT) = 1.5 × ULN;

3. Liver function: aspartate aminotransferase (AST) and alanine in the absence of liver metastasis Transaminase (ALT) = 2.5 × ULN; In case of liver metastasis, AST and alt = 5.0 × ULN;Total bilirubin in serum (TBIL) = 1.5 × ULN (patients known to have Gilbert syndrome Only when total bilirubin = 3 × ULN, direct bilirubin = 1.5 × In the case of ULN, it will be Consider);

4. Renal function: creatinine = 1.5 × ULN or creatinine clearance = 40 ml/min (according to Cockcroft-Gault formula);

5. Cardiac function: left ventricular ejection fraction (LVEF) = 50%; ECG is basically normal,QT interval (QTCF) corrected by fridericia formula: male = 450 ms, female = 470 ms;

8. Qualified patients (male and female) with fertility must agree to give drugs during the trial or at the end of the trial Use reliable contraceptive methods (hormone or barrier method or abstinence) with their partners for at least 6 months Etc.); Women of childbearing age (refer to the appendix of the text for the definition) within 7 days before the first use of the investigational drug The pregnancy test must be negative.

Exclusion criteria:

1. Known allergy to, or hypersensitivity to, VIC-1911, osimertinib, or any of the excipient ingredients

2. Subject has previously discontinued osimertinib due to toxicity or other safety events Interstitial lung disease/non-infectious pneumonia; Symptoms or signs of severe arrhythmia with prolonged QTc interval; Symptomatic congestive heart failure

3. Other side effects caused by previous treatment did not alleviate to CTCAE= grade 1, alopecia or otherwise

4. A history of ocular disease was present, and the patient had occlusion of central or branch retinal arteries or veins with visual acuity Significant decline, or a history of visual impairment due to other retinal diseases as determined by an ophthalmologist or Performance

5. The following infectious diseases are known to be active, such as:

Human immunodeficiency virus antibody (HIV-AB) positive; Hepatitis B surface antigen (HBsAg) positive and HBV-DNA exceeding the upper limit of normal value; Hepatitis C virus antibody (HCV-AB) positive and HCV RNA positive

6. Other active infections requiring intravenous antibiotics within 7 days before administration;

7. Use of potent CYP inducer 28 days before administration or within 5 half-lives of the drug, whichever is longer A guide or inhibitor;

8. Had undergone a major surgical procedure within 28 days prior to drug administration or was expected to require a major procedure during the trial Surgery;

9. Received the latest antitumor therapy (chemotherapy, targeted therapy, radiotherapy, immunotherapy, biological therapy) Therapy or endocrine therapy), less than 5 half-lives after or after the first administration of the drug Less than 28 days (whichever is longer). Had received the drug within 14 days before the first dose with definite resistance The effect of traditional Chinese medicine on tumor;

10. A history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

uncontrolled hypertension (systolic blood pressure >160 mmHg or shu) after standard clinical treatment Tension >100 mmHg for more than 4 weeks); I have severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias that require clinical intervention, Degree II-III atrioventricular block, etc Patients with grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria Any arterial thromboembolic event, including but not limited to myocardial infarction, occurred within 6 months prior to dosing Plug, transient ischemic attack, unstable angina pectoris or other grade 3 or above cardiovascular and cerebrovascular disease Events; Any factor that increases the risk of prolonged QTc intervals or arrhythmias: e.g., heart failure, hypokalemia Haemaemia, congenital long QT syndrome, or the use of anything known to prolong the QT interval Concomitant drugs (see Appendix of the main text for details), except antibiotics used to prevent or treat infection;

11. Parenchymal or meningeal metastases with clinical symptoms were not eligible for inclusion as judged by the investigator. Such as Previous systemic and radical brain metastases therapy (radiotherapy or surgery) proved stable on imaging It has been maintained for at least 28 days and has stopped systemic hormone therapy for more than 14 days without clinical symptoms Is allowed to enter the group;

12. Suffers from hematological malignancies;

13. Other malignant tumors have been diagnosed within 5 years before the first use of the study drug; Effectively treated skin Basal cell carcinoma, squamous cell carcinoma of the skin, and/or effectively resected cervical cancer in situ and/or breast Except the cancer;

14. Inability to swallow medication;

15. Gastrointestinal diseases that may affect the absorption or tolerability of the trial drug, such as refractory or screening CTCAE> grade 2 gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, etc.);

16. Patients with difficulty in venous blood collection;

17. Women who have a positive pregnancy test or are breastfeeding during the screening period;

18. Administration of an investigational drug that has undergone clinical trials of other drugs within 28 days prior to administration;

19. Previous treatment with other Aurora kinase inhibitors;

20. Patients with a history of blood donation or blood loss of more than 400 mL 3 months before screening;

21. Anything else that, in the opinion of the investigator, may affect the subject to provide informed consent or follow the protocol Circumstances, or the subject's participation in the trial may affect the results of the trial or their own safety.

Related Conditions & MeSH terms

• Advanced Non-small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• VIC-1911
VIC-1911 tablets for oral administration
• Osimertinib Mesylate Tablets
Osimertinib tablets for oral administration

Locations

Country	Name	City	State
China	Zhangli	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment emergent adverse events (safety and tolerability)	Safety and tolerability assessed by adverse events(AEs) and serious adverse events (SAEs)	36 months
Secondary	Pharmacokinetic PK parameters	Cmax	C1D1 and C1D4 in the first period
Secondary	Time to Response	Length of time from the date of first dose of study drug to the first evidence of objective response (CR,PR)	Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
Secondary	Disease Control Rate	Proportion of subjects with best response of CR, PR or stable disease (SD)	Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
Secondary	Progression-Free Survival	Length of time from the date of first dose of study drug to the first evidence of disease progression or death, whichever is earlier	Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
Secondary	Overall Survival	Length of time from the date of first dose of study drug to date of death from any cause	Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month